Biblio Discovery — Demo Discovery Service

11 results for "Arlene M Gallagher"

Showing 1–11 · 0.30 seconds · RSS

  1. Journal Article Full text

    The Impact of the Choice of Data Source in Record Linkage Studies Estimating Mortality in Venous Thromboembolism.

    Arlene M Gallagher; Tim Williams; Hubert G M Leufkens et al.

    PLoS ONE, Vol. 11 No. 2 · 2016 · English · DOAJ Scopus

    Linked electronic healthcare databases are increasingly being used in observational research. The objective of this study was to investigate the impact of the choice of data source in estimating mortality following VTE, with a secondary aim to investigate the influence of the denominator…

    Also available at: PLOS

  2. Journal Article Full text

    Risk of Death and Cardiovascular Outcomes with Thiazolidinediones: A Study with the General Practice Research Database and Secondary Care Data

    Arlene M. Gallagher; Liam Smeeth; Suzie Seabroke et al.

    PLoS ONE, Vol. 6 No. 12 · 2011 · English · PLOS Scopus

    Objective: To describe the likely extent of confounding in evaluating the risks of cardiovascular (CV) events and mortality in patients using diabetes medication. Methods: The General Practice Research Database was used to identify inception cohorts of insulin and different oral antidiabetics. An…

    Also available at: DOAJ

  3. Journal Article

    Risk of fracture with thiazolidinediones: an individual patient data meta-analysis

    Marloes T Bazelier; Frank ede Vries; Peter eVestergaard et al.

    Frontiers in Endocrinology, Vol. 4 · 2013 · English · DOAJ Scopus

    Background: The use of thiazolidinediones (TZDs) has been associated with increased fracture risks. Our aim was to estimate the risk of fracture with TZDs in three different healthcare registries, using exactly the same study design, and to perform an individual patient data meta-analysis of these…

  4. Journal Article

    Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs

    M Elle Saine; Dean M Carbonari; Craig W Newcomb et al.

    BMC Pharmacology and Toxicology, Vol. 16 No. 1 · 2015 · English · DOAJ Scopus

    Abstract Background The patterns and determinants of saxagliptin use among patients with type 2 diabetes mellitus (T2DM) are unknown in real-world settings. We compared the characteristics of T2DM patients who were new initiators of saxagliptin to those who were new initiators of non-dipeptidyl…

  5. Journal Article

    Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes

    Qing Liu; Sean Hennessy; Qufei Wu et al.

    BMJ Open Diabetes Research & Care, Vol. 5 No. 1 · 2017 · English · DOAJ Scopus

    Objective To evaluate the risk of serious adverse events among patients with type 2 diabetes mellitus initiating saxagliptin compared with oral antidiabetic drugs (OADs) in classes other than dipeptidyl peptidase-4 (DPP-4) inhibitors.Research design and methods Cohort studies using 2009–2014 data…

  6. Journal Article Full text

    Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing

    James S. Floyd; Katarzyna M. Bloch; Jennifer A. Brody et al.

    PLOS ONE, Vol. 14 No. 6 · 2019 · English · PLOS Scopus

    Aims: Statin-related myopathy (SRM), which includes rhabdomyolysis, is an uncommon but important adverse drug reaction because the number of people prescribed statins world-wide is large. Previous association studies of common genetic variants have had limited success in identifying a genetic basis…

    Also available at: DOAJ